Key result
Synthetic angiotensin II linked to ~75% NED reduction in pediatric catecholamine-resistant vasodilatory shock survivors.
Why the study?
Experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock was limited.
Does synthetic human angiotensin II improve mean arterial pressure and reduce vasopressor requirements in critically ill children with catecholamine-resistant vasodilatory shock?
Observational (n=23)
No
Does synthetic human angiotensin II improve mean arterial pressure and reduce vasopressor requirements in critically ill children with catecholamine-resistant vasodilatory shock?
In critically ill children with catecholamine-resistant vasodilatory shock, synthetic angiotensin II may improve hemodynamics and reduce vasopressor requirements, though overall mortality remains high.
Should not change practice in pediatric vasodilatory shock; hypothesis-generating for prospective angiotensin II trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tezel et al. (2023) conducted an observational in Catecholamine-resistant vasodilatory shock (CRVS) (n=23). Synthetic human angiotensin II was evaluated on Norepinephrine equivalent (NED) and mean arterial pressure (MAP). Synthetic angiotensin II reduced vasopressor needs in pediatric catecholamine-resistant vasodilatory shock; survivors had greater NED reduction than non-survivors (-75% vs +2.1%, p=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: